TEL AVIV – Israel’s said on Thursday it raised $60 million in funding and received clearance from the U.S. Food and Drug Administration for its smartphone-based urine albumin test to aid in diagnosing chronic kidney disease. smartphone-based urine albumin test

The funding round was led by Corner Ventures with participation by Joy Capital Ventures and previous investors Ansonia Holdings, Aleph and Samsung NEXT. The company has raised $95 million to date.

The funds will be used to accelerate’s global expansion and product development.

“The smartphone has the potential to be the great equalizer of healthcare,” said Yonatan Adiri, founder and CEO of

This is the company’s second FDA clearance. Last year it received clearance for its at-home, smartphone-based urinalysis test kit and now has a partnership with Boots UK, placing its test kits in hundreds of pharmacies.